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ABSTRACT Despite the strikingly high worldwide prevalence of vulvovaginal can-
didiasis (VVC), treatment options for recurrent VVC (RVVC) remain limited, with
many women experiencing failed clinical treatment with frontline azoles. Further,
the cause of onset and recurrence of disease is largely unknown, with few studies
identifying potential mechanisms of treatment failure. This study aimed to assess
a panel of clinical samples from healthy women and those with RVVC to investi-
gate the influence of Candida, the vaginal microbiome, and how their interaction
influences disease pathology. 16S rRNA sequencing characterized disease by a
reduction in specific health-associated Lactobacillus species, such as Lactobacillus
crispatus, coupled with an increase in Lactobacillus iners. In vitro analysis showed
that Candida albicans clinical isolates are capable of heterogeneous biofilm forma-
tion, and we found the presence of hyphae and C. albicans aggregates in vaginal
lavage fluid. Additionally, the ability of Lactobacillus to inhibit C. albicans biofilm
formation and biofilm-related gene expression was demonstrated. Using RNA
sequencing technology, we were able to identify a possible mechanism by which
L. crispatus may contribute to re-establishing a healthy vaginal environment
through amino acid acquisition from C. albicans. This study highlights the poten-
tial formation and impact of Candida biofilms in RVVC. Additionally, it suggests
that RVVC is not entirely due to an arbitrary switch in C. albicans from commensal
to pathogen and that understanding interactions between this yeast and vaginal
Lactobacillus species may be crucial to elucidating the cause of RVVC and develop-
ing appropriate therapies.
IMPORTANCE RVVC is a significant burden, both economically and for women's
health, but its prevalence is poorly documented globally due to the levels of self-
treatment. Identifying triggers for development and recurrence of VVC and the
pathogenesis of the microbes involved could considerably improve prevention
and treatment options for women with recurrent, azole-resistant cases. This study
therefore aimed to examine the interkingdom dynamics from healthy women and
those with RVVC using next-generation sequencing techniques and to further
investigate the molecular interactions between C. albicans and L. crispatus in a rel-
evant biofilm coculture system.
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Fungal infections are becoming increasingly recognized as a substantial health bur-den on the global population. Over 1 billion people are estimated to suffer from
fungal infections each year, resulting in over 1.5 million deaths (1). These infections are
commonly associated with mucosal sites, such as the vagina, gut, and oral cavity.
Vaginitis is estimated to account for up to 7% of all visits to gynecologists and for up
to 10 million general practitioner (GP) appointments annually (2). Vulvovaginal candi-
diasis (VVC) is not a reportable disease and is often self-treated with over-the-counter
antifungal agents; therefore, its exact prevalence and distribution are impossible to
determine. VVC is reported as the second most common cause of vaginitis, and it is
estimated that 75% of women will suffer from VVC in their childbearing years, with up
to 140 million of these women developing recurrent VVC (RVVC), defined as $4 cases
within 1 year (3, 4). These recurrent cases are debilitating, impact quality of life, and
are associated with psychological stress, pruritis, and discomfort (5, 6). VVC is associ-
ated with various risk factors, including the use of antibiotics and contraceptives, new
sexual partners, and allergic responses to Candida antigens; however, no distinguish-
able cause has been identified (7, 8).
The biofilm-forming yeast Candida albicans is reported as the predominant patho-
gen responsible for up to 90% of VVC infections (4). C. albicans is commonly isolated
from the vagina as an asymptomatic commensal with a carriage rate of up to 33% in
premenopausal women (9). Other non-albicans Candida (NAC) species, most com-
monly Candida glabrata, C. parapsilosis, C. dubliniensis and C. krusei, account for 10 to
20% of VVC infections and are associated with complicated VVC, which exhibits less
severe symptoms than C. albicans VVC but higher recurrence rates (10, 11). C. albicans
has been shown to form biofilms on vaginal mucosa both ex vivo and in vivo by identi-
fication of significant fungal load, biofilm architecture, and extracellular matrix using
confocal and electron microscopy (12). This is a possible contributing factor to failed
clinical treatment resulting in persistent and recurrent VVC. Despite the identification
of Candida biofilms on vaginal mucosa, the predicted therapeutic challenge this
presents in VVC is still disputed. Other studies challenge the hypothesis of vaginal bio-
films and instead suggest other factors, such as germ tube formation and polymicro-
bial tissue invasion, as more critical features of VVC (13, 14).
The vaginal microbiome is somewhat unique in that a healthy microbiome is associ-
ated with a less diverse community of microbes, predominantly lactobacilli such as
Lactobacillus crispatus, L. iners, L. gasseri, and L. jensenii (15). Dysbiosis of the vaginal
microbiome leads to an increase in species diversity, with fewer lactobacilli and greater
numbers of pathogenic anaerobes, such as Gardnerella and Prevotella (16, 17). In
healthy women, lactic acid bacteria (LAB) are thought to be responsible for maintain-
ing a homeostatic microbiome by inhibiting growth and adhesion of other microbes
via the production of secreted metabolites, such as lactic acid, biosurfactants, bacterio-
cins, and H2O2. L. crispatus, a potent producer of both D- and L- isomers of lactic acid as
well as H2O2, is a prevalent commensal of the healthy vaginal environment in various
microbiome studies (18, 19). Additionally, it is known to secrete the L-lactic acid isomer
that has been extensively studied for its ability to lower vaginal pH, elicit anti-inflam-
matory responses, and inhibit microbial colonization (20, 21).
A single dose of oral fluconazole is sufficient to treat sporadic C. albicans VVC in 80 to
90% of cases (22). Treatment of VVC caused by NAC is more complicated, requiring pro-
longed suppressive azole therapies, and is often unsuccessful. The efficacy of therapeutics
such as amphotericin B and boric acid has been assessed for the treatment of RVVC. Both
drugs when delivered intravaginally for 14 to 21days were found to be effective in
around 70% of patients (23, 24). Candida species, predominantly C. albicans, are known to
form thick tenacious biofilms that dramatically increase tolerance to antifungal drugs
commonly used in the treatment of VVC, such as fluconazole, miconazole, and flucytosine
(25). Indeed, sessile cells have been shown to tolerate antifungal concentrations 1,000-
fold greater than their planktonic counterparts (26). Therefore, an alternative therapeutic
strategy for RVVC may be through microbiome replacement therapy in the form of
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Lactobacillus probiotics (27). Probiotic therapy involves the administration of live
microorganisms, which directly results in a health benefit for the patient (28). Due to
the diversity of lactobacilli within the vaginal microbiome, it is difficult to estimate
which species would be most important to replace with probiotic therapy. One study
evaluated Lactobacillus plantarum P17630 combined with the standard treatment of
clotrimazole for 3 days and concluded a potential resolution of vaginal discomfort
(29). The probiotic potential of secreted metabolites of Lactobacillus against C. albi-
cans has been summarized, identifying gaps in our knowledge of fungal-Lactobacillus
interactions that could lead to improved treatment options (30–33). Currently, no
probiotic therapies have been approved for the treatment of VVC/RVVC.
Clearly, RVVC is a significant burden, both economically and for women’s health,
and its prevalence is poorly documented globally due to the levels of self-treatment.
Identifying triggers for development and recurrence of VVC and the pathogenesis of
the microbes involved could considerably improve prevention and treatment options
for women with recurrent, azole-resistant cases. This study therefore aimed to examine
the interkingdom dynamics in healthy women and those with RVVC using next-genera-
tion sequencing techniques and to further investigate the molecular interactions
between C. albicans and L. crispatus in a relevant biofilm coculture system.
RESULTS
Clinical and microbiological assessment of patient samples. The mechanisms
behind the shift in candidal species from commensal to pathogenic yeast seen in RVVC
onset remain poorly understood. The cause of infection is likely multifactorial, and
here, we aimed to assess whether fungal or bacterial load may influence disease by
using samples collected from healthy individuals (n=60) and women with RVVC
(n=40). Clinical assessment was used to confirm RVVC diagnosis, which was further
validated by significantly increased interleukin 8 (IL-8) expression levels (P, 0.0001)
(Table S1). Patient demographic data collected through questionnaires found that
patients had suffered from RVVC for an average of 8months, with an average of
1month since they last received treatment. Although higher numbers of women with
RVVC had culturable Candida than healthy women, quantitative PCR (qPCR) analysis
revealed Candida to be detectable in all but 2 patients.
First, the levels of Candida present in the clinical samples were quantified by deter-
mining numbers of CFU per milliliter, in addition to total yeast and bacterial DNA quan-
tified by qPCR colony-forming equivalents (CFE) per milliliter (Fig. 1). Quantities of
yeast CFU/ml showed a significant increase in Candida load in samples, from approxi-
mately 2 103 CFU/ml in healthy patients to 2.3 104 CFU/ml in RVVC patients
(P=0.0079) (Fig. 1a). Similarly, when assessed by qPCR, a significant increase of around
1.3-log was observed in patients with RVVC, to 3.8 105 CFE/ml (P=0.024), as shown
in Fig. 1b. These data suggest that increased levels of Candida could be a contributing
factor to disease pathology or an indicator for VVC onset and subsequent recurrence.
Additionally, Candida load was observed with respect to patient metadata. Although a
slight reduction of between 0.5 and 1 log was observed in patients with disease for
over 7months, this was not significant (data not shown). An increase in fungal load
from 1 104 to 5 104 CFU/ml was observed in women who had received treatment
for RVVC longer than 1month prior to sample collection (P=0.021) (Fig. S2). Bacterial
load was found to be comparable at ;8 107 CFE/ml between healthy women and
those with RVVC (P=0.779) (Fig. 1c). Finally, correlation between bacterial and fungal
load found significantly higher levels of Candida DNA per CFE/ml of bacterial DNA
present in RVVC compared with healthy controls (P=0.0001) (Fig. 1d).
Taxonomic classification of health and RVVC. To determine the bacterial taxa
present in healthy women and those with RVVC, we performed 16S rRNA sequencing
on DNA extracted from swab samples (Fig. 2). At the genus level, a Lactobacillus-domi-
nated environment, accounting for up to 75% of the microbiome, was observed in
both cohorts, with similar levels of diversity and the vaginal anaerobes Gardnerella and
Prevotella (Fig. 2a and b). Atopobium was found to be slightly higher in healthy patients
Interactions of Candida and Lactobacillus in RVVC














































and Bifidobacterium slightly lower. A limitation of our microbiome analysis was the
inability to distinguish between some Lactobacillus species (including Lactobacillus aci-
dophilus, L. casei, and L. gasseri). For this reason, these species are grouped as
“Lactobacillus spp., including L. crispatus.” However, sequencing of a subset of samples
using the Oxford Nanopore Technologies MinION sequencer confirmed accuracy to
the species level (Fig. S3) (34). When viewed at the species level, although not signifi-
cant following P value correction, subtle differences in bacterial taxa were observed
between healthy controls and RVVC, particularly among Lactobacillus species (Fig. 3).
Most notable was the reduction in levels of specific Lactobacillus species. This included
L. jensenii and to a greater extent L. crispatus, which fell from 44% in healthy patients
to 30% in those with RVVC (Fig. 3a and b). Interestingly, this reduction was coupled
with an increase in L. iners from just 19% in healthy samples to 40% in RVVC.
Additionally, when predicted using random forest plots, levels of L. iners were sug-
gested to be the most distinct between samples from healthy women and those from
women with RVVC (Fig. 3c).
To investigate the influence of bacterial taxa further, microbial populations were
observed with respect to patient metadata (Fig. 4). In patients with culturable Candida
compared with those who were culture negative, a reduction in Lactobacillus species
including L. crispatus from 44% to 29%, coupled with an increase in L. iners from 23% to
35%, was observed, similar to the RVVC profile (Fig. 4a). Further, L. iners was predicted to
be the second most likely organism to define presence or absence of Candida using ran-
dom forest analysis to identify important features (Fig. 4c). When observed with respect
to the length of time patients had had RVVC, an intermediate profile between health and
disease was observed in patients with disease for less than 6months, showing a slight
reduction in L. crispatus from 45% to 40% (Fig. 4c). Conversely, patients with disease for
between 6 and 12months had a profile similar to that seen in RVVC, with increased levels
FIG 1 Fungal burden is elevated in women with RVVC while bacterial load remains unchanged. To assess
fungal load, patient lavage was incubated on Candida Chromogenic agar plates and colonies counted after 48
h (a). For calculation of CFE/ml, the ITS region of Candida was amplified using genus-specific primers (b). Levels
of bacteria DNA were also assessed molecularly by amplification of the 16S rRNA region (c). Correlation
between bacterial and fungal burden was also observed (d). Data are means 6 standard deviations (SD).
Statistical significance was calculated using unpaired t tests with Welch’s correction, as data did not share
equal standard deviations (*, P, 0.05; **, P, 0.01).
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of L. iners from 19% to 44% (Fig. 4d). Additionally, bacterial communities present were
observed with respect to contraceptives used at the time of sampling (Fig. S4). At the spe-
cies level, a notable similarity in the composition of healthy patients and those using hor-
monal contraception, in contrast to patients using a contraceptive device or no contra-
ception, was observed. The most important feature identified at the species level was
predicted to be Atopobium vaginae. It is predicted that this organism is present in higher
numbers in healthy patients and those using hormonal contraceptives and lower num-
bers in patients using either no contraception or contraceptive devices. Additionally, a
contrasting pattern is shown for L. iners, which is predicted to be highest in patients using
contraceptive devices. The microbiome was then observed with respect to how recently
patients had received antifungal intervention to treat RVVC (Fig. S5). A gradual reduction
in Lactobacillus species, including L. crispatus, was observed, from 44% in healthy samples
to 34% and 23% in patients treated within a month and more than a month before sam-
pling, respectively. Patients treated more than 1 month before sampling were predicted
to have an intermediate profile between those of healthy women and women treated for
RVVC more recently.
Finally, correlation between the vaginal microbiome and Candida load (CFE/ml) was
observed with respect to patient metadata (Fig. S6). Megasphaera, often associated
with vaginal dysbiosis, was found to be significantly positively correlated with
increased fungal load (P, 0.05) (Fig. S6). Although not significant, genera such as
Dialister, Bacteroides, and Shuttleworthia were correlated with higher fungal loads in
RVVC. Further, Lactobacillus was significantly negatively correlated with Candida in
healthy samples, and to a lesser extent in RVVC (P, 0.05). Although none were found
to be significant, correlations observed with respect to recent treatment identified
slight negative correlations between genera such as Streptococcus, Gardnerella, and
Lactobacillus with increasing time since last RVVC intervention. Conversely, genera
FIG 2 Bacterial genera present in healthy women and those with RVVC. DNA extracted from swab samples was
used for 16S rRNA Illumina sequencing (n= 100). Bacterial diversity measured by Shannon index (a) and genus-
level taxa identification and percentage abundance of microbial populations present (b) in health and RVVC.
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such as Prevotella, Morganella, and Sneathia were found to be positively correlated
with increasing time since treatment. Streptococcus, Prevotella, and Clostridium were
found to be positively correlated with increased RVVC episodes. However, genera such
as Shuttleworthia, Lactobacillus, and Atopobium were found to be negatively correlated
with increasing RVVC episodes.
Influence of Candida biofilm formation in RVVC. Candida clinical isolates were
obtained from lavage samples by culture on Candida chromogenic agar. Following
incubation, a total of 33 isolates were obtained, 9 from healthy individuals and 24 from
patients with RVVC. Isolate identification was confirmed for all isolates using matrix-
assisted laser desorption ionization–time of flight (MALDI-TOF) (Fig. 5a). Consistent
with previous RVVC studies, C. albicans was found to account for 73% of the Candida
species isolated within our patient subset. Other NAC species, more commonly associ-
ated with RVVC, accounted for the remaining 27%. Following identification, biofilm
forming capabilities of clinical isolates was assessed (Fig. 5b). C. albicans was capable
of forming dense biofilms with clear heterogeneity between isolates. Isolates were
grouped as low biofilm formers (LBF) if the absorbance reading of their total biomass
fell below the first quartile (,0.185). Similarly, high biofilm formers (HBF) were
observed when total biomass was above the third quartile (.0.854). Intermediate bio-
film formers (IBF) had biomass readings between these values. Minimal biomass was
observed in NAC species. Additionally, when lavage fluid from an RVVC patient with a
C. albicans isolate capable of dense biofilm formation was viewed microscopically,
FIG 3 Hydrogen peroxide-producing lactobacillus strains are reduced during RVVC infection, resulting in an L. iners-dominated microbiome. Species-level
identification of bacterial taxa present in healthy women (a) and those with RVVC (b). Random forest plot showing the most distinct species-level taxa
present between healthy women and those with RVVC (c).
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hyphal forms and bacterium-yeast aggregates could be clearly observed (Fig. 5c). To
further investigate and validate that Candida biofilms are a defined clinical entity,
expression levels of key biofilm-related genes were measured from patients’ vaginal la-
vage fluid. These data show detectable levels of expression of genes involved in hyphal
morphogenesis, biofilm formation, and pathogenesis in Candida isolates present in
patients with RVVC, including HWP1, ECE1, ALS3, and SAP (Table S2).
Antagonism of Lactobacillus and C. albicans. Next, to assess the interactions
between Lactobacillus species and C. albicans, 7 Lactobacillus species were selected and
their effects on C. albicans biofilm formation in coculture observed (Fig. 6). When grown
together for 24 h, a reduction in overall biomass was observed in all Lactobacillus species
from an absorbance reading of 3.0 to approximately 2.5. This reduction was particularly
prominent in Lactobacillus rhamnosus, where biomass was reduced to an absorbance
value of 2.0 (Fig. 6a). However, when C. albicans was allowed to form a biofilm before
addition of Lactobacillus, this effect was less pronounced and in some cases absent
(Fig. 6b). To further analyze the biomass reduction, C. albicans biofilm-related gene
expression was assessed following coculture with L. rhamnosus and L. iners. L. rhamnosus
is often studied for its probiotic effect against C. albicans. Although L. iners is a vaginal
commensal, it has not been found to inhibit fungal growth or biofilm formation. The
two organisms differentially interacted with C. albicans, with L. rhamnosus downregulat-
ing all biofilm-related gene expression after incubation for 20 h and 24 h (Fig. 6c). Gene
expression was reduced by ;4-fold for HWP1 and between 0.5- and 1-fold for ALS3 and
ECE1 in both growth conditions. L. iners downregulated expression of ECE1 and, to a
FIG 4 Species-level taxon abundance relative to patient metadata. Species-level bacterial taxa based on presence/absence of Candida (a) and length of
time with disease (b). Random forest plots showing distinct bacterial taxa present in each analysis (c and d).
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lesser extent, HWP1 after incubation for 24 h. However, when added to a preexisting C.
albicans biofilm, L. iners resulted in upregulation of ECE1 and ALS3.
To further understand how antagonistic features of Lactobacillus impact C. albicans,
we utilized transcriptome sequencing (RNA-Seq) of C. albicans following coculture with
L. crispatus. L. crispatus was selected for RNA sequencing analysis, as opposed to L.
rhamnosus, as it is not a commensal of the vaginal environment and is capable of only
transient colonization. Further, L. crispatus is one of the most prevalent Lactobacillus
species in the vaginal microbiome, and its antagonism toward C. albicans has been
demonstrated in previous studies (31–33, 35). Initially, multivariate analysis by princi-
pal-component analysis (PCA) was unable to identify distinct clusters of gene expres-
sion in early dual-species biofilms (Fig. S8). Subsequently, there was no significant up-
or downregulation in early dual-species biofilm transcripts compared to single-species
controls (P. 0.05). For this reason, further analysis compared expression in mature 24-
h single- and dual-species biofilms only. Heat map analysis of normalized log2 fold
change in gene expression between single- and dual-species 24-h biofilms with L.
crispatus revealed upregulation of many genes involved in amino acid biosynthesis
and breakdown in dual-species biofilms (ARG8, ILV1, and HIS5) (Fig. 7). Interestingly,
the PRY1 gene, which codes for a secreted protein associated with virulence in the
presence of lactate in C. albicans, was found to be downregulated in dual-species bio-
films (log2 fold change = 25.35). A list of some of the key genes and their functions is
presented in Table 1. Gene ontology (GO) term analysis was utilized to determine the
functionality of differentially expressed genes in single- and dual-species 24-h biofilms.
FIG 5 Vaginal Candida isolates from patients with RVVC are capable of heterogeneous biofilm formation. A
total of 33 Candida clinical isolates were isolated from lavage samples. MALDI-TOF was used to identify each
isolate and assess species distribution (“Others” comprises 1 isolate each of C. dubliniensis, C. parapsilosis, and
C. krusei) (a). Candida isolates from healthy women (n= 9) and those with RVVC (n= 24) were assessed for
biofilm-forming capabilities by crystal violet staining (b). Vaginal lavage was stained with calcofluor white
(CFW) for 1 h at 37°C before imaging (c). Images are representative of C. albicans aggregates and hyphae
observed in lavage fluid from a patient with an HBF isolate. White arrows represent pseudohyphal/hyphal
formation, and red arrows depict cell aggregates. Data are means 6 SD. Statistical analysis was performed
using unpaired t-tests (****, P, 0.0001).
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Genes expressed in L. crispatus dual-species biofilms were mainly responsible for
amino acid biosynthesis and some metabolic and transaminase activity (Fig. 8a and b).
Despite upregulation of these amino acid biosynthesis and metabolism pathways in C.
albicans, expression of BAT21 and ILV1 in dual-species biofilms suggests that C. albicans
was in a state of amino acid starvation (Fig. 8c).
Given the antagonism observed between the two organisms, we next aimed to
investigate the in vitro probiotic potential of L. crispatus against C. albicans infection in
a complex biofilm model (Fig. 9). After 2 consecutive days of probiotic treatment, a
slight reduction in total and live C. albicans composition within the biofilm was
observed; however, this was not significant (P=0.55 and P=0.16, respectively) (Fig. 9a
and b). Following a 4-day treatment regimen with L. crispatus, total C. albicans compo-
sition decreased (P, 0.05), with reduced levels of live fungal DNA. When the total fold
reduction in C. albicans from untreated biofilms was assessed, the greatest probiotic
effect was observed at 48 h posttreatment (Fig. 9c).
DISCUSSION
Unlike systemic and oral candidiasis, RVVC affects immunocompetent women with
an incidence rate of up to 8% in women of child-bearing age; hence, it is the most
FIG 6 Lactobacillus species display antagonism with C. albicans in vitro. To observe inhibitory effects
of Lactobacillus against C. albicans biofilm formation, C. albicans and a panel of Lactobacillus species
were cocultured in THB/RPMI (1:1) medium in 5% CO2 for 24 h (a), or C. albicans was grown for 4 h
prior to addition of Lactobacillus species for 20 h (b). C. albicans biofilm-associated gene expression
was measured in the presence of L. rhamnosus, which is associated with health, and L. iners, which is
hypothesized to indicate dysbiosis. The mean log fold change relative to single species C. albicans
biofilms is shown (c). Data are means and SD.
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prevalent human infection caused by the pathogenic yeast, with approximately 140
million cases annually (36). Despite this, the disease remains largely understudied in
the field of women’s health. A better understanding of RVVC at a molecular level may
be crucial in unearthing potential targets for much-desired therapeutics. This study
aimed to assess a panel of 100 clinical isolates to investigate fungal influence and
changes in bacterial communities and to use an RNA sequencing approach to analyze
potential interkingdom interactions contributing to pathology.
Clinical and microbiological assessment of patient samples. The estimated vagi-
nal commensal carriage rate of Candida is 33% (9). We observed the presence of
FIG 7 Differential expression analysis of C. albicans single-species and C. albicans–L. crispatus dual-species biofilms. Heat map displaying the top 50
significantly differentially expressed genes in C. albicans between single- and dual-species 24-h biofilms (P, 0.05).
McKloud et al.














































Candida both by culture and by qPCR and found that 15% and 60% of samples from
healthy women and those with RVVC had culturable Candida, respectively, and all but
2 samples were positive by qPCR. As expected, levels of the inflammatory biomarker
IL-8 and Candida DNA were found to be significantly higher in patients with RVVC, con-
firmatory of clinical diagnosis. It is important to note that these clinical samples are
from women regularly attending sexual health clinics, and those who have suffered
from RVVC for longer may be more likely to be receiving antifungal treatment. This
should be considered when interpreting Candida CFE/ml data in this study, as
untreated RVVC may present differently.
Taxonomic classification of health and RVVC. Unlike the vaginal microbiome dur-
ing bacterial vaginosis (BV), the microbial communities present during VVC have been
shown to be similar to those present in healthy women at the phylum and genus levels
(37, 38). Our study confirms these findings, as we report a Lactobacillus-dominated
population with vaginal anaerobes, including Gardnerella, Prevotella, and Atopobium,
with no significant differences in diversity or composition between the two cohorts at
the genus level. This suggests that the functional capacity of the bacterial species
found in healthy women and those with RVVC may play a more crucial role in pathol-
ogy. We observed a reduction in specific Lactobacillus species, including those associ-
ated with maintaining health due to their ability to produce L-lactic acid and H2O2,
such as L. crispatus and L. jensenii. This reduction coupled with an increase of L. iners
has been shown previously and is thought to be indicative of vaginal dysbiosis (37).
We report that this loss of health-associated Lactobacillus species and increase of L.
iners is also seen specifically in patients with positive Candida cultures and those who
have suffered from RVVC for.6months.
We show an L. iners-dominated microbiome in women using contraceptive devices
or no contraception, which suggests that hormonal contraceptives may be less dysbiotic
to the vaginal flora or have the potential to maintain a more health-like microbiome
than contraceptive devices. Additionally, recent antifungal use revealed a microbial pro-
file similar to those of healthy patients, suggesting that, although somewhat effective,
the current antifungal treatments for RVVC do not alter the microbiome to a sufficient
level to reintroduce a health-like state. This is evident with the microbiome reverting to
favor a disease-like environment after less than 1 month. This is similar to results found
by other authors, who reported a transition from disease to an intermediate state follow-
ing fluconazole treatment (16). Although not associated with vaginal dysbiosis, the ge-
nus Shuttleworthia was positively correlated with Candida load and increased time
between treatments and is often observed in high levels in vaginal microbiome studies
(39). Regardless of disease status, Lactobacillus was negatively correlated with the pres-
ence of Candida as well as increased numbers of episodes and time between treatments,





arg3 Arginine and citrulline biosynthesis 3.72897
his5 Histidine biosynthesis 3.474415
lys22 Lysine biosynthesis 3.469013
bul1 Protein ubiquitination 3.254671
arg4 Arginine biosynthesis/metabolism 2.810158
atf1 N-Acetyltransferase activity 2.704281
arg8 Arginine biosynthesis/metabolism 2.695885
aro3 Phenylalanine, tyrosine, and tryptophan biosynthesis 2.411573
his4 Histidine, purine, and pyrimidine biosynthesis 2.352654
his3 Histidine, purine, and pyrimidine biosynthesis 2.340446
bat21 Leucine, valine, and isoleucine biosynthesis/breakdown 2.284677
ilv1 Leucine, valine, and isoleucine biosynthesis, threonine breakdown 2.049845
leu42 Leucine, valine, and isoleucine biosynthesis 1.945496
Interactions of Candida and Lactobacillus in RVVC














































indicating the potential protection from Candida overgrowth provided by vaginal lacto-
bacilli. These findings may be important for future studies investigating RVVC. It is
hypothesized that changes within Candida allow it to switch from asymptomatic com-
mensal to pathogenic yeast. It may now be more important to study RVVC with a specific
focus on the microbes present during RVVC, specifically Lactobacillus, and interkingdom
interactions which may influence this pathogenic switch in Candida.
Influence of Candida biofilm formation in RVVC. Consistent with epidemiological
reports, we observed C. albicans to be the most common isolate identified, followed by
C. glabrata. Though C. albicans has been shown to form biofilms on vaginal mucosa and
Candida clinical isolates have been shown to form biofilms in vitro, the presence of bio-
films during RVVC infection is still disputed (37). Despite evidence to the contrary, our
study has shown heterogeneous biofilm formation in C. albicans RVVC isolates and shows
clear visualization of C. albicans hyphae and aggregates in lavage fluid from a patient
with RVVC. Moreover, transcripts from genes associated with biofilm formation were
readily detected from vaginal lavage fluid. Therefore, Candida biofilm formation within
the vagina should not be discounted as a potential cause of failed clinical treatment and
subsequent recurrence of disease. We also show the capacity of various Lactobacillus spe-
cies to inhibit C. albicans biofilm formation when cocultured. L. rhamnosus has been stud-
ied extensively for its potential as a probiotic and has been shown to prevent adhesion of
C. albicans to mucosal surfaces (39). Here, we show the ability of L. rhamnosus to down-
regulate C. albicans biofilm-related gene expression. In contrast, L. iners results in upregu-
lation of both ALS3 and ECE1. This is consistent with previous findings suggesting that L.
iners may be indicative of a dysbiotic vaginal environment and should not be considered
as a probiotic intervention for C. albicans infections (40).
FIG 8 Gene networks of gene ontology (GO) terms and upregulated genes in dual-species biofilms. Constructed gene networks of GO terms in 24-h
biofilms with L. crispatus (a). Important biological, cellular, and molecular functions in dual-species biofilms with L. crispatus (b). Log2 fold change of key
gene expression in C. albicans from single- to dual-species biofilms with L. crispatus (c). Nodes are colored by significance. All GO terms have an adjusted P
value of ,0.05. Networks were created using ClueGO.
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Antagonism of Lactobacillus and C. albicans. In our transcriptomic analyses we
aimed to examine mechanisms of reported antagonism between C. albicans and L.
crispatus. It has previously been shown in Lactobacillus clinical isolates that secreted
metabolites can remain at low levels from 72 or 120 h of incubation, which may
account for the delay in interaction (41). The in vivo vaginal pH is thought to be ,4.5;
however, in this dual-species model, the pH was sustained between 6 and 7. It is possi-
ble that in the in vivo setting, the lower environmental pH could affect C. albicans gene
expression. Nonetheless, the stability of the neutral pH throughout this experiment
dictates that any transcriptomic changes observed are not due to acidification of the
medium and are a result of interactions between C. albicans and L. crispatus.
Transaminase activity is primarily associated with a-amino acid breakdown and bio-
synthesis. It has been shown in a model of Saccharomyces cerevisiae, L. lactis, and L.
plantarum that in nitrogen-rich environments, yeasts secrete an array of metabolites,
primarily amino acids, thereby facilitating the growth of lactobacilli (42, 43). The upreg-
ulation of various amino acid biosynthesis processes in our study may be attributed to
this nutrient cross-feeding. As opposed to a convenient coincidence, this may be a
deliberate process by which L. crispatus is able to drive synthesis of amino acids in C.
albicans, as well as suppressing arginine breakdown, to facilitate its own metabolism
and growth. The upregulation of the amino acid starvation indicators bat21 and ilv1 in
dual-species biofilms shows that despite the upregulation of various amino acid bio-
synthesis processes, C. albicans is unable to utilize them. This may be a contributing
factor in the process by which L. crispatus is able to outcompete Candida during VVC
and potentially re-establish a healthy microbiome. Furthermore, the pry1 gene, encod-
ing a secreted glycoprotein associated with virulence and sterol binding in the
FIG 9 Twice-daily addition of L. crispatus reduces C. albicans load within a complex biofilm model in vitro. The
potential probiotic properties of L. crispatus against C. albicans were assessed in a 11-species biofilm model
treated twice daily with L. crispatus. Live/dead qPCR allowed quantification of percentage composition of total
(a) and live (b) C. albicans DNA within the biofilm. Average fold change in the C. albicans percentage
composition from the untreated 11-species biofilm is also shown (c). Data are means and SD. Statistical analysis
was performed using paired t tests comparing raw CFE values (*, P, 0.05).
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presence of lactate, was found to be downregulated in dual-species biofilms (44). Thus,
L. crispatus may possess a mechanism by which it can suppress lactate-associated viru-
lence in C. albicans. Species-specific differential transcriptomic profiles in vaginal candi-
diasis have been demonstrated, and therefore, interactions between Lactobacillus and
other prevalent Candida species should be considered (44). These data collectively
show a potentially probiotic effect of L. crispatus against C. albicans in nonacidic envi-
ronments. This antagonism is governed by the overproduction of amino acids from C.
albicans, which may facilitate restoration of a healthy microbiome through lactobacil-
lus proliferation.
Finally, we investigated the potential probiotic effect of L. crispatus against C. albicans
within a complex biofilm model. Although studies have assessed the inhibitory effect of
L. crispatus against C. albicans monospecies biofilms (33, 45, 46), to our knowledge, this is
the first report of L. crispatus reducing C. albicans composition within a polymicrobial bio-
film model in vitro. Our data support other studies confirming the probiotic potential of L.
crispatus against C. albicans biofilm infections.
This study assessed the vaginal microbiome only of women in the United Kingdom;
results may differ based on geographical prevalence of different Candida and Lactobacillus
species. Additionally, a larger sample set may allow for statistically significant differences
in the microbiome of women with VVC and healthy controls. It may be useful for future
studies to observe transcriptional changes of C. albicans with other health-associated vagi-
nal Lactobacillus species, such as L. jensenii and L. gasseri.
In conclusion, Candida burden is increased in women with RVVC compared to asymp-
tomatic controls and continues to increase following antifungal intervention due to re-
sistant communities. The reduction of protective H2O2-producing Lactobacillus species
during RVVC is exacerbated in women who have RVVC for longer than 6months, those
who have culturable Candida, those who use no contraception or a contraceptive device,
and those who are treated less frequently. Additionally, demonstration of biofilm-form-
ing capabilities and imaging of C. albicans aggregates in patient lavage fluid, as well as
the expression of C. albicans biofilm-related genes, suggest that there is a high probabil-
ity of Candida biofilm formation in the vagina during RVVC. The subsequent increased
antifungal tolerance of these biofilms may allow Candida to persist within the vagina
and cause recurrence of VVC. Our study suggests that it may be important to view RVVC
as a result of fluctuation in antagonistic interkingdom interactions between Candida and
Lactobacillus, potentially as a result of Candida biofilm formation. Additionally, we show
for the first time the potential of L. crispatus to re-establish a healthy vaginal environment
through altered gene expression in C. albicans and the ability to reduce fungal composi-
tion in a complex biofilm model. Lactobacilli are key protective organisms in the healthy
vaginal microbiome, and their antagonistic effect on Candida is of clinical significance. As
demonstrated within our clinical study, there was a decrease in levels of protective
Lactobacillus species in RVVC patients. The decrease of levels of these species also inver-
sely correlated with an increase in fungal load. Further understanding of this antagonism
offers potential avenues for improving women’s health through probiotic/prebiotic regi-
mens. This interaction could prove impactful in the development of novel mechanisms
for antifungal treatments, and therefore, further studies of this interaction are required.
MATERIALS ANDMETHODS
Patient recruitment and collection of clinical samples. One hundred women aged 18 and over
attending Glasgow Sandyford Sexual Health Clinic were enrolled in the study. Patient recruitment and
obtaining of written informed consent were carried out at the clinic from prospective participants after
they had read the patient information sheet. If the patient chose to participate, a questionnaire was
completed and given to the clinician in charge of the study (R.M.). Patients with current, confirmed
symptomatic RVVC (n= 40) were recruited as well as asymptomatic women attending the clinic for con-
traceptive intrauterine device (IUD) implantation, acting as a healthy cohort (n= 60). This study was
granted ethical approval by the Sheffield Research Ethics Committee (16/YH/0310). Patients were
excluded from the study if they had prior or active bacterial vaginosis, were pregnant, immunosup-
pressed, menstruating, or menopausal, or had taken antibiotics/antifungals within 7 days prior to sam-
pling. From each patient, one high vaginal swab (HVS) and one cervicovaginal lavage fluid sample (CVL)
were collected. A graphical representation of sample collection and processing can be found in Fig. S1.
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Detection of inflammatory biomarkers in CVL fluid. CVL fluid supernatants were recovered by cen-
trifugation. Levels of IL-8 were measured by enzyme-linked immunosorbent assay (ELISA) (Invitrogen,
Paisley, UK), following the manufacturer’s instructions. CVL fluid was diluted 1:2, and absorbances were
measured using a spectrophotometer at 450nm and 570nm.
Quantification of microbial load by quantitative PCR. HVS samples were used to extract DNA for
quantitative PCR (qPCR) analysis of Candida/bacterial burden. DNA was extracted using the QIAamp
DNA minikit, per the manufacturer’s instructions (Qiagen, Crawley, UK), and qPCR was used to quantify
fungal and bacterial load in each sample. Primers specific to the conserved Candida internal transcribed
spacer (ITS) rRNA gene (47) were used to determine Candida load. For bacterial load, primers and probe
specific to the 16S rRNA gene were used (48, 49). Primer sequences can be found at https://www
.glasgowbiofilms.co.uk/. The total qPCR volume was 20 ml, with 1 ml of extracted DNA, 500 mM forward/
reverse primers, and UV-treated RNase-free H2O. For 16S, 250 mM probe and 2 TaqMan universal PCR
master mix (Thermo Scientific, Loughborough, UK) was used; 2 Fast SYBR green PCR master mix
(Thermo Scientific, Loughborough, UK) was used for ITS primers. qPCR was carried out using a Step-One
Plus real-time PCR machine (Life Technologies, Paisley, UK) with the following thermal conditions: an
activation step of 50°C for 2min and 95°C for 10min followed by 40 cycles of 95°C for 10 s to denature
and annealing at 60°C for 30 s. Standard curves constructed from serially diluted DNA of C. albicans
SC5314 and Escherichia coli K-12 were used to extrapolate Candida and bacterial colony-forming equiva-
lents (CFE) per milliliter, respectively, as described previously (50).
Preparation of 16S amplicon libraries for Illumina sequencing. To observe bacterial populations
in the samples, 16S rRNA sequencing was performed. Briefly, previously extracted HVS DNA was
used to sequence the 16S rRNA V4 region using the Illumina MiSeq sequencing platform (Edinburgh
Genomics) using 2  250-bp paired-end reads. Amplification of the V4 region was achieved using
fusion Golay adaptors barcoded on the reverse strand as described previously (51) using the univer-
sal primer 515F (59-TATGGTAATTGTGTGCCAGCMGCCGCGGTAA-39) and reverse primer 806R (59-
AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT-39). Quality control (QC) of reads was performed within
the R package DADA2 (v1.14.1). Reads were filtered and trimmed using standard error rates before
reads were denoised and merged and chimeric sequences removed. Amplicon sequence variants
(ASV) were annotated by the Silva 132 16S rRNA database with an exact match to the ASV. ASV and
taxonomic assignments were utilized for downstream data analysis.
Identification and biofilm screening of Candida species from cervicovaginal lavage fluid.
Lavage fluid samples were screened for presence and identification of Candida species using Colorex
Candida chromogenic agar (E&O Laboratories Ltd., Bonnybridge, UK) and matrix-assisted laser desorp-
tion ionization–time of flight (MALDI-TOF) mass spectrometry. For culture identification, 20 ml of CVL
samples was spread across the surface of a chromogenic agar plate before 48 h of incubation at 30°C.
The color of the colonies cultured was used to determine Candida species, colony numbers were used
to calculate the number of CFU per milliliter. Clinical isolates were then stored on beads in glycerol in
Microbank vials (Pro-Lab Diagnostics, Cheshire, UK) at 280°C. Each isolate was then subsequently identi-
fied by MALDI-TOF analysis using a Bruker Microflex system, comparing recorded spectra to the Bruker
database to confirm identify to the species level.
Candida clinical isolates were assessed for biofilm-forming capabilities by crystal violet assay. Candida
isolates (n=33) were cultured on Sabouraud’s (SAB) agar for 48 h at 30°C. For biofilm formation, overnight
cultures were grown in yeast extract peptone dextrose (YPD) at 30°C. Cultures were washed twice with
phosphate-buffered saline (PBS) and standardized in RPMI 1640 medium to a final cell density of 1 106
CFU/ml. Eight biofilms of each isolate were grown in 96-well, flat-bottomed polystyrene microtiter plates
for 24 h at 37°C before biomass measured by the crystal violet assay (52). For visualization of Candida aggre-
gates, 30 ml of CVL was stained with calcofluor white (CFW) to a final concentration of 0.06mg/ml for 1 h at
37°C, before being imaged using the EVOS live cell imaging system (Thermo Scientific, Loughborough, UK).
Antagonism of C. albicans and Lactobacillus in coculture. The ability of the following 7 Lactobacillus
strains to inhibit C. albicans SC5314 biofilm formation was assessed: L. casei ATCC 393, L. fermentum
ATCC 14931, L. crispatus ATCC 33820, L. iners DSMZ 13335, L. salivarius ATCC 11741, L. jensenii ATCC
25258 and L. rhamnosus ATCC 7469. Overnight cultures of C. albicans and Lactobacillus were grown in
YPD and de Man, Rogosa, and Sharpe (MRS; Merck UK) medium, respectively, under appropriate culture
conditions. For these experiments, we used an optimized medium of Todd-Hewitt broth (THB; Merck
UK) supplemented with 10mM menadione and 10mg/ml hemin (Thermo Fisher) and mixed 1:1 with
RPMI (referred to here as 1:1 broth), as described previously for coculture experiments (53). For biofilm
formation, overnight cultures were standardized to 1 106 CFU/ml for C. albicans and 1 107 CFU/ml
for Lactobacillus species in 1:1 medium. Eight biofilms of each C. albicans-Lactobacillus pair were incu-
bated in 5% CO2 for 24 h. In addition, C. albicans biofilms were grown for 4 h prior to Lactobacillus being
added for 20 h, with biomass quantified using the crystal violet assay.
C. albicans biofilm-related gene expression analysis. To assess C. albicans biofilm-related gene expres-
sion, RNA was extracted from dual-species biofilms using the PureLink RNA minikit (Thermo Scientific,
Loughborough, UK), following manufacturer’s instructions. In brief, 2mg of RNA was converted to cDNA
using a high-capacity cDNA reverse transcription kit (Thermo Scientific, Loughborough, UK) and 1 ml was
used in a 20-ml qPCR with 10 ml 2 Fast SYBR green PCR master mix, 1 ml forward/reverse primer,
and UV-treated H2O. Primer sequences can be found at https://www.glasgowbiofilms.co.uk/ (54–56).
Gene expression was analyzed in duplicate on three separate occasions; no-reverse-transcription
(NRT) controls and no-template controls (NTC) were included throughout. Gene expression was nor-
malized to the ACT1 housekeeping gene and calculated using the DDCT method (57).
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In vitro transcriptomic analysis of C. albicans interactions with L. crispatus. C. albicans and L.
crispatus type strains SC5314 and ATCC 33820, respectively, were used for transcriptional analysis in this
component of the study. Biofilms were formed as described above. Cultures were washed twice with
PBS and standardized in 1:1 broth to 1 106 CFU/ml for C. albicans and 1 107 CFU/ml for L. crispatus.
Initially, C. albicans biofilms were grown in T-75 cell culture flasks (Corning, USA) for 4 h in 5% CO2.
Following incubation, medium was removed, and biofilms washed before L. crispatus was added for an
additional 2, 4, or 20 h. At each time point, the medium was removed and biofilms were washed with
PBS before being scraped into 1ml of RNAlater (Thermo Scientific, Loughborough, UK). Spent medium
from biofilms was retained, and pH was monitored throughout the experiment. RNA was extracted from
microbial biofilms using the RiboPure RNA purification kit for yeast (Thermo Scientific, Loughborough,
UK), following manufacturer’s instructions. Integrity of RNA was assessed using a Bioanalyzer system, and
genome-wide Candida transcripts were sequenced using the Illumina NOVASeq6000 sequencing platform
(Edinburgh Genomics). FastQC was used to assign quality scores to the produced reads, and Illumina
adaptors and poor-quality reads were trimmed using Trimmomatic (V0.38). Hisat2 (v2.1.0) was then used
to align the resulting reads to a reference C. albicans genome (http://www.candidagenome.org/) before
the number of sequences that were aligned to each gene was counted using HTSeq-count (v0.11.0). The
counted genes were subsequently imported into RStudio, and the DESeq2 package was used to analyze
the differentially expressed genes. A summarized illustration of the experimental and bioinformatics pipe-
lines can be found in Fig. S1b and c.
Investigating the probiotic potential of L. crispatus in a complex biofilmmodel. Complex 11-spe-
cies biofilms were formed as described previously by our group with slight modifications (58). Overnight
broths of each organism were standardized in 1:1 medium prior to addition to the biofilm on 13-mm
discs. For probiotic treatment, each biofilm was treated twice daily (12 h intervals) with 5 107 CFU/ml
of L. crispatus for 5min before treatment was removed, biofilms washed 3 times in PBS and fresh media
replaced. On day 3, after 4 probiotic treatments, 48-h biofilms were analyzed for compositional analysis.
On day 5, following 8 probiotic treatments, 96-h biofilms were removed for compositional analysis. At
each time point, biofilms were washed 3 times and sonicated in 1ml of PBS at 35 kHz for 10min to
remove biomass. Sonicates were split in two, with one sample having 5ml of 10mM propidium monoa-
zide (PMA) added to it for the quantification of live C. albicans DNA. PMA is a DNA-intercalating dye
used to bind DNA from dead cells or those with a compromised membrane following exposure to a hal-
ogen light (59, 60). The other sample, lacking PMA, allowed quantification of total C. albicans DNA per
biofilm. All samples were incubated in the dark for 10min, then placed on ice, and exposed to a 650-W
halogen light for 5min. DNA was then extracted using the QIAamp DNA minikit, per the manufacturer’s
instructions (Qiagen, Crawley, UK). To a 20-ml qPCR mixture, 1 ml of biofilm DNA was added; the mixture
contained 10 ml Fast SYBR green master mix, 1 ml of 10mM C. albicans forward and reverse primers, and
UV-treated nuclease-free water. Primer sequences can be found at https://www.glasgowbiofilms.co.uk/.
The following thermal profile was used: 95°C for 2min and 40 cycles of 95°C for 3 s followed by 55°C for
30 s. Samples were assessed in duplicate from 2 separate experiments. Fungal CFE/ml were then calcu-
lated as described above.
Statistical analysis. Microbiome figures were created using MicrobiomeAnalyst (61). Bacterial diver-
sity and abundance plots were made using alpha diversity and stacked-bar charts, respectively. Random
forest plots were used to predict important species present under each condition. Transcriptome pipe-
line figures were constructed using BioRender and differential gene expression plots using the DESeq2
package in RStudio. Gene ontology networks were constructed using ClueGO software, available
through Cytoscape (62). All other figures and analyses were performed in GraphPad Prism (version 8;
GraphPad, La Jolla, CA, USA).
Data availability. Microbiome data are deposited under the accession number PRJNA719953 in the
SRA database.
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